Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib with R-DHAP or R-DHAOx in B-cell Lymphomas
NCT02055924Phase 1Terminated
- Sponsor
- LYSARC
- Start
- May 2014
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ibrutinib in B cell lymphoma and mantle cell lymphoma (MCL) (5 arms), sponsored by LYSARC. Primary endpoint: Incidence rate of Dose-Limiting Toxicities at 21 days. Started May 2014; status: terminated.
02
Drugs
ibrutinib
03
Conditions
B cell lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02055924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055924.